Clinical trials in Japan

9,213 studies list at least one site in Japan. 1,276 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-25.

Studies

Recruiting first, then most recently updated. Showing 50 of 9,213 — search for more.

• A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresEnrolling by invitationNCT05076617Phase 3
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT05923073Phase 3
• A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringEnrolling by invitationNCT06788509Phase 1
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)RecruitingNCT06393374Phase 3
• A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNot yet recruitingNCT07668336Phase 3
• A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder CancerRecruitingNCT06319820Phase 3
• A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)Not yet recruitingNCT07794774Phase 3
• JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCCRecruitingNCT04892173Phase 3
• A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)Not yet recruitingNCT07794761Phase 3
• Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder CancerRecruitingNCT06510374Phase 3
• A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Phase 3
• A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck CancerRecruitingNCT06385080Phase 1/2
• A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)RecruitingNCT04811560Phase 1/2
• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)RecruitingNCT06312176Phase 3
• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyRecruitingNCT06750094Phase 3
• A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe DiseaseRecruitingNCT06679140Phase 3
• This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.RecruitingNCT06758401Phase 3
• A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative NeoplasmsRecruitingNCT06150157Phase 1
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal CancerRecruitingNCT06662786Phase 3
• A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Phase 3
• A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic ArthritisRecruitingNCT06807424Phase 3
• A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingNCT05201781Phase 4
• A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe EczemaRecruitingNCT06807268Phase 3
• A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe EczemaRecruitingNCT06807281Phase 3
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)RecruitingNCT06103864Phase 3
• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)RecruitingNCT05139017Phase 2/3
• A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)RecruitingNCT05912517Phase 3
• Dominantly Inherited Alzheimer Network (DIAN)RecruitingNCT00869817
• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureRecruitingNCT06742723Phase 3
• A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease DementiaRecruitingNCT06803823Phase 2
• Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)RecruitingNCT05327114Phase 2/3
• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)RecruitingNCT06136650Phase 3
• A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This ConditionRecruitingNCT05519475Phase 2
• Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)RecruitingNCT04924075Phase 2
• A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsRecruitingNCT06663332Phase 3
• A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04634552Phase 2
• A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4RecruitingNCT06078553
• Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaRecruitingNCT04925479Phase 1/2
• A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerRecruitingNCT06820463Phase 2
• Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06005493Phase 1/2
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingNCT06841354Phase 3
• Observational Study Protocol: LIVER-RRecruitingNCT06252753
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingNCT06852222Phase 3
• Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsRecruitingNCT06932263Phase 2
• A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)RecruitingNCT06890884Phase 2
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingNCT06966700Phase 3
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06172478Phase 2
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT06233461Phase 2
• A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)RecruitingNCT06717347Phase 3
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerRecruitingNCT06868277Phase 3